Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months.

Alain Saraux; Thomas Barnetche; Guy Baudens; Isabelle Idier; Flore Delaporte; Pascal Hilliquin

Poster communications

Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months.

Alain Saraux ^{1, 2} Thomas Barnetche ³ Guy Baudens ⁴ Isabelle Idier ⁵ Flore Delaporte ⁶ Pascal Hilliquin ⁷

1 CHU - BREST - Rhumato - CHRU Brest - Service de Rhumatologie

2 LBAI - Lymphocyte B et Auto-immunité

3 SERVICE DE RHUMATOLOGIE - Rhumatologie Bordeaux

4 Cabinet de Rhumatologie, Valenciennes

5 Chugai Pharma France, Paris La Défense

6 Laboratoire Roche [Boulogne-Billancourt]

7 Centre Hospitalier Sud Francilien

Document type :

Poster communications

Domain :

Life Sciences [q-bio] / Immunology

Complete list of metadatas

https://hal.univ-brest.fr/hal-02151122
Contributor : Geneviève Michel <>
Submitted on : Friday, June 7, 2019 - 4:59:02 PM
Last modification on : Saturday, June 8, 2019 - 1:35:48 AM

Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months.

Identifiers

Collections

Citation

Export

Metrics

33

Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months.

Identifiers

Collections

Citation

Export

Share

Metrics

33